论文部分内容阅读
目的:探讨莫沙必利对于功能性消化不良患者的;临床治疗效果。方法:随机选取自2015年1月至2016年12月期间进行治疗的84例功能性消化不良患者作为研究对象,并根据患者入院治疗的顺序,将其分成观察组和对照组,各42例。对照组患者使用多潘立酮进行对症治疗,观察组患者则采用莫沙必利进行治疗,治疗结束之后,比较两组患者的治疗效果以及发生不良反应以及治疗6个月后患者病情复发的概率。结果:两组患者各自的治疗结束之后,观察组患者的总有效率要明显高于对照组患者的总有效率,且观察组患者出现不良反应的概率也要明显低于对照组患者发生不良反应的概率,此外,观察组患者的复发率也低于对照组患者的复发率,用于比较的两组数据之间的差异较明显,具有统计学意义(P<0.05)。结论:使用莫沙必利治疗功能性消化不良,其治疗效果有很大的提升,此外,采用莫沙必利进行功能性消化不良的治疗,患者出现不良反应以及复发的概率显著降低,可见该药具有极佳的安全性,适宜在该病症的临床治疗中推广应用。
Objective: To investigate the effect of mosapride on patients with functional dyspepsia. Methods: A total of 84 patients with functional dyspepsia who were treated from January 2015 to December 2016 were selected as the study subjects, and were divided into observation group and control group according to the order of admission and treatment, and 42 patients . Patients in the control group were given symptomatic treatment with domperidone, and patients in the observation group were treated with mosapride. After the treatment was completed, the treatment effect and adverse reactions in both groups were compared, and the probability of recurrence was 6 months after the treatment. Results: After the end of treatment, the total effective rate in the observation group was significantly higher than that in the control group, and the adverse reaction rate in the observation group was significantly lower than that in the control group . In addition, the recurrence rate of patients in the observation group was also lower than that in the control group. The difference between the two data sets for comparison was statistically significant (P <0.05). Conclusion: Mosapride treatment of functional dyspepsia, the treatment has greatly improved, in addition, the use of mosapride for functional dyspepsia, patients with adverse reactions and the probability of relapse was significantly reduced, we can see that the Medicine has excellent safety, suitable for the clinical treatment of the disease to promote the application.